The whole warrant accounting thing is B.S. I don't know why accounting rules with warrants allow you to have a huge loss, simply because the stock went up. It creates a headline which ultimately looks like hell, and the fact that quant programs pick up on EPS hits and misses makes this number look a lot worse than it really was.
7.85 gap just filled in AH
Go figure. what's next.
case in point:
"InPlay: Ariad Pharm misses by $0.16Briefing.com(Wed 4:39PM EDT)"
I do agree, however, the PACE news is pretty awesome. Data at ASH for the pivotal trial (preliminary follow-up) and 6 months ahead for full enrollment.
I would think that by end of Q1'12
this trial should have enough data to be fully read out.
BTW, if this market didn't look like another flash crash on beta names was coming, I'd be a buyer tomorrow.
